HTLV-I Associated Leukemia/Lymphoma: Epidemiology, Biology, and Treatment

  • Richard Siegel
  • Ronald Gartenhaus
  • Timothy Kuzel
Part of the Cancer Treatment and Research book series (CTAR, volume 104)


Adult T-cell leukemia,lymphoma (ATL) was first described in 1977 by Uchiyama et al., who detailed the clinical and hematologic features in 16 patients.’ They found that these patients had leukemic cells that were morphologically heterogeneous with deeply indented or lobulated nuclei. They frequently had involvement of the skin, lymph nodes, liver, and spleen. The most striking feature of this group was that 13 of them were born in the same region of Southern Japan, even though they eventually migrated from this region.Poiesz et al. isolated the retrovirus HTLV-I from a patient initially thought to have cutaneous T-cell lymphoma, but now believed to have had ATL.2It is now accepted that HTLV-I is the causative agent of adult T-cell leukemia,lymphoma (ATL). HTLV-I causes several diseases, including tropical spastic paraparesis,HTLV-I-associated myelopathy (TSP,HAM), uveitis, and infective dermatitis.


Acquir Immune Infective Dermatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Uchiyama T Yodoi J, Sagawa K, et al: Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 50:481–492, 1977PubMedGoogle Scholar
  2. 2.
    Poiesz BJ, Ruscetti FW, Gazdar AF, et al: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci 77:7415–7419, 1980PubMedCrossRefGoogle Scholar
  3. 3.
    Gross DJ, Kavanaugh A: HTLV-I. Int J Dermatol 29:161–165, 1990PubMedCrossRefGoogle Scholar
  4. 4.
    Manns A, Hisada M, La Grenade L: Human T-lymphotropic virus type I infection. Lancet 353:1951–1958, 1999PubMedCrossRefGoogle Scholar
  5. 5.
    Pawson R, Mufti GJ, Pagliuca A: Management of adult T-cell leukaemia,lymphoma. Br J Hematol 100:453–458, 1998CrossRefGoogle Scholar
  6. 6.
    Yamaguchi K: Human T-lymphotropic virus type I in Japan. Lancet 343:213–216, 1994PubMedCrossRefGoogle Scholar
  7. 7.
    Takatsuki K, Matsuoka M, Yamaguchi K: Adult T-Cell Leukemia in Japan.. J Acquir Immune Defic Synch Hum Retrovirol 13(S1):S15–19, 1996CrossRefGoogle Scholar
  8. 8.
    Mueller N, Okayama A, Stuver S, et al: Findings from the Miyazaki cohort study. J Acquir Immune Defic Syndr Hum Retrovirol 13(S1):S2–S7, 1996PubMedCrossRefGoogle Scholar
  9. 9.
    Taylor GP: The epidemiology of HTLV-I in Europe.. J Acquir Immune Defic Syndr Hum Retrovirol 13(S1):S8–S14, 1996PubMedCrossRefGoogle Scholar
  10. 10.
    Hanchard B: Adult T-cell leukemia,lymphoma in Jamaica: 1986–1995. J Acquir Immune Defic Syndr Hum Retrovirol 13(S1):S20–S25, 1996PubMedCrossRefGoogle Scholar
  11. 11.
    Tubiana N, Lejeune C, Lecaer F, et al: T-Lymphoma associated with HTLV-I outside the Caribbean and Japan. Lancet:337, 1985Google Scholar
  12. 12.
    Gibbs WN, Lofters WS, Campbell M, et al: Non-Hodgkin Lymphoma in Jamaica and its relation to adult T-cell Leukemia,lymphoma. Ann Intern Med 106:361–368, 1987PubMedGoogle Scholar
  13. 13.
    Kaplan JE, Khabbaz RF, Murphy EL, et al: Male-to-female transmission of human T-cell lymphotropic virus types I and H: Association with viral load. J Acquir Immune Defic Syndr Hum Retrovirol 12:193–201, 1996PubMedCrossRefGoogle Scholar
  14. 14.
    Nyambi PN, Ville Y, Louwagie J, et al: Mother-to-child transmission of human T-cell lymphotropic virus types I and II (HTLV-I,II) in Gabon: A prospective follow-up of 4 years. J Acquir Immune Defic Synch Hum Retrovirol 12:187–192, 1996CrossRefGoogle Scholar
  15. 15.
    Komuro A, Hayami M, Fujii H, et al: Vertical transmission of adult T-cell leukaemia virus. Lancet i:240, 1983CrossRefGoogle Scholar
  16. 16.
    Chen YC, Wang CH, Su IJ, et al: Infection of human T-cell leukemia virus type I and development of human T-cell leukemia,lymphoma in patients with hematologic neoplasms: A possible linkage to blood transfusion. Blood 74:388–394, 1989PubMedGoogle Scholar
  17. 17.
    Giesecke J: HTLV screening of Swedish blood donors. Lancet 345:978, 1995PubMedCrossRefGoogle Scholar
  18. 18.
    Osame M, Izumo S, Igata A, et al: Blood transfusion and HTLV-I associated myelopathy. Lancet ii:104–105, 1986CrossRefGoogle Scholar
  19. 19.
    Brennan M, Runganga J, Barbara JA, et al: Prevalence of antibodies to human T cell leukaemia,lymphoma virus in blood donors in north London. Br Med J 307:1235–1239, 1993CrossRefGoogle Scholar
  20. 20.
    Dalgleish AG: Human T-cell leukaemia,lymphoma virus and blood donation. Br Med J 307:1224–1225, 1993CrossRefGoogle Scholar
  21. 21.
    Coste J, Lemaire JM, Barin F, et al: HTLV-I,II antibodies in French blood donors. Lancet 335:1167–1168, 1990PubMedCrossRefGoogle Scholar
  22. 22.
    Yoshida M: Molecular biology of HTLV-I: Recent progress. J Acquir Immune Defic Synch Hum Retrovirol 13(S1):S63–S68, 1996CrossRefGoogle Scholar
  23. 23.
    Franchini G: Molecular mechanisms of human T-cell leukemia,lymphotropic virus type I infection. Blood 86:3619–3639, 1995PubMedGoogle Scholar
  24. 24.
    Nagafuji K, Harada M, Teshima T, et al: Hematopoietic progenitor cells from patients with adult T-cell leukemia-lymphoma are not infected with human T-cell leukemia virus type 1. Blood 82:2823–2828, 1993PubMedGoogle Scholar
  25. 25.
    Grassman R, Dengler C, Muller-Fleckenstein I, et al: Transformation to continuous growth of primary human T lymphocytes by human T-cell leukemia virus type I X-region genes transduced by a Herpesvirus saimiri vector. Proc Natl Acad Sci 86:3351–3355, 1989CrossRefGoogle Scholar
  26. 26.
    Suzuki T, Kitao S, Matsushime H, et al: HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p164Aand counteracts its inhibitory activity towards CDK4. EMBO 15:1607–1614, 1996Google Scholar
  27. 27.
    Cereseto A, Mulloy JC, Franchini G: Insights on the pathogenicity of human Tlymphotropic,leukemia virus types I and II. J Acquir Immune Defic Syndr 13(S 1):S69–S75, 1996Google Scholar
  28. 28.
    Hisada M, Okayama A, Shiryo S, et al: Risk factors for adult T-cell leukemia among carriers of human T-lymphotropic virus type I. Blood 92:3557–3561, 1998PubMedGoogle Scholar
  29. 29.
    Furukawa Y, Osame M, Kubota R, et al: Human T-cell leukemia virus type-1 (HTLV-1) tax is expressed at the same level in infected cells of HTLV-1-associated myelopathy or tropical spastic paraphrases patients as in asymptomatic carriers but at a lower level in adult T-cell leukemia cells. Blood 85:1865–1870, 1995PubMedGoogle Scholar
  30. 30.
    Kinoshita K, Amagaski T, Ikeda S, et al: Preleukemic state of adult T-cell leukemia: Abnormal T lymphocytosis induced by human adult T-cell leukemia-lymphoma virus. Blood 66:120–127, 1985PubMedGoogle Scholar
  31. 31.
    Hanchard B, LaGrenade L, Carberry C, et al: Childhood infective dermatitis evolving into adult T-cell leukaemia after 17 years. Lancet 338:1593–1594, 1991PubMedCrossRefGoogle Scholar
  32. 32.
    Manns A, Hanchard B, Morgan OS, et al: Human leukocyte antigen class II alleles associated with human T-cell lymphotropic virus type I infection and adult T-cell leukemia,lymphoma in a black population. J Nail Cancer Inst 90:617–622, 1998CrossRefGoogle Scholar
  33. 33.
    Arima N, Matsushita K, Obata H, et al: NF-KB involvement in the activation of primary adult T-cell leukemia cells and its clinical implications. Exp Hem 27:1168–1175, 1999CrossRefGoogle Scholar
  34. 34.
    Shimoyama M, and members of the Lymphoma Study Group: Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. Br J Hem 79:428–437, 1991CrossRefGoogle Scholar
  35. 35.
    Takemoto S, Matsuoka M, Yamaguchi K, et al: A novel diagnostic method of adult T-cell leukemia: Monoclonal integration of human T-cell lymphotropic virus type I provirus DNA detected by inverse polymerase chain reaction. Blood 84:3080–3085, 1994PubMedGoogle Scholar
  36. 36.
    Bunn PA, Schecter GP, Jaffe E, et al: Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med 309:257–264, 1983PubMedCrossRefGoogle Scholar
  37. 37.
    Kawano F, Yamaguchi K, Nishimura H, et al: Variation in the clinical courses of adult T-cell leukemia. Cancer 55:851–856, 1985PubMedCrossRefGoogle Scholar
  38. 38.
    Pagliuca A, Layton DM, Allen S, et al: Hyperinfection with strongyloides after treatment for adult T-cell leukaemia-lymphoma in an African immigrant. Br Med J 297:1456–1457, 1988CrossRefGoogle Scholar
  39. 39.
    Taguchi H, Kobayashi M, Miyoshi I: Immunosuppression by HTLV-I infection. Lancet 337:308, 1991CrossRefGoogle Scholar
  40. 40.
    Lymphoma Study Group: Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study. Leuk Res 15:81090, 1991Google Scholar
  41. 41.
    Shimoyama M, Ota K, Kikuchi M, et al: Major prognostic factors of adult patients with advanced T-cell lymphoma,leukemia. J Clin Oncol 6:1088–1097, 1988PubMedGoogle Scholar
  42. 42.
    Yamada Y, Murata K, Kamihira S, et al: Prognostic significance of the proportion of Ki-67-positive cells in adult T-cell leukemia. Cancer 67:2605–2609, 1991PubMedCrossRefGoogle Scholar
  43. 43.
    Kamihira S, Sohda H, Atogami S, et al: Phenotypic diversity and prognosis of adult T-cell leukemia. Leuk Res 16:435–441, 1992PubMedCrossRefGoogle Scholar
  44. 44.
    Sadamori N, Ikeda S, Yamaguchi K, et al: Serum deoxythymidine kinase in adult T-cell leukemia-lymphoma and its related disorders. Leuk Res 15:99–103, 1991PubMedCrossRefGoogle Scholar
  45. 45.
    Kamihira S, Atogami S, Sohda H, et al: Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer 73:2753–2758, 1994PubMedCrossRefGoogle Scholar
  46. 46.
    Tsukasaki K, Tsushima H, Yamamura M, et al: Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: Frequent clonal change at crisis from indolent disease. Blood 89:948–956, 1997PubMedGoogle Scholar
  47. 47.
    Hayami Y, Komatsu H, lida S, et al: Microsattelite instability as a potential marker for poor prognosis in adult T-cell leukemia,lymphoma. Leukemia & Lymphoma 32:345–349, 1999Google Scholar
  48. 48.
    Renjifo B, Chou K, Ramirez LS, et al: Human T-cell leukemia virus type I (HTLV-I) molecular genotypes and disease outcome. J Acquir Immune Defic Syndr Hum Retrovirol 13(S1):S146–S153, 1996PubMedCrossRefGoogle Scholar
  49. 49.
    Peter SA, Cervantes JF: Hypercalcemia associated with adult T-cell leukemia,lymphoma (ATL). J Nall Med Assoc. 87:746–748, 1995Google Scholar
  50. 50.
    Ikeda K, Inoue D, Okazaki R, et al: Parathyroid hormone-related peptide in hypercalcemia associated with adult T cell leukemia,lymphoma: Molecular and cellular mechanism of parathyroid hormone-related peptide overexpression in HTLV-Iinfected T cells. Miner Electrolyte Metab 21:166–170, 1995PubMedGoogle Scholar
  51. 51.
    Dodd RC, Winkler CF, Williams ME, et al: Calcitriol levels in hypercalcemic patients with adult T-cell lymphoma. Arch Intern Med 146:1971–1972, 1986PubMedCrossRefGoogle Scholar
  52. 52.
    Fukumoto S, Matsumoto T, Ikeda K, et al: Clinical evidence of calcium metabolism in adult T-cell leukemia,lymphoma. Arch Intern Med 148:921–925, 1988PubMedCrossRefGoogle Scholar
  53. 53.
    Motokura T, Fukumoto S, Matsumoto T, et al: Parathyroid hormone-related protein in adult T-cell leukemia,lymphoma. Ann Intern Med 111:484–488, 1989PubMedGoogle Scholar
  54. 54.
    Ikeda K, Ohno H, Hane M, Yokoi H, et al: Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: Evidence for elevated levels in plasma from patients with adult T-cell leukemia,lymphoma and B-cell lymphoma. J Clin Endocrinol Metab 79:1322–1327, 1994PubMedCrossRefGoogle Scholar
  55. 55.
    Ikeda K, Okazaki R, Inoue D, et al: Transcription of the gene for parathyroid hormone-related peptide from the human is activated through a cAMP-dependent pathway by prostaglandin E, in HTLV-I-infected T cells. J Biol Chem 268:1174–1179, 1993PubMedGoogle Scholar
  56. 56.
    Ikeda K, Okazaki R, Inoue D, et al: Interleukin-2 increases production and secretion of parathyroid hormone-related peptide by human T cell leukemia virus type I-infected T cells: Possible role in hypercalcemia associated with adult T-cell leukemia. Endocrinol 132:2551–2556, 1993CrossRefGoogle Scholar
  57. 57.
    Ejima E, Rosenblatt J, Massari M, et al: Cell-type-specific transactivation of the parathyroid hormone-related protein gene promoter by the human T-cell leukemia virus type I (HTLV-I) tax and HTLV-II tax proteins. Blood 81:1017–1024, 1993PubMedGoogle Scholar
  58. 58.
    Watanabe T, Yamaguchi K, Takatsuki K, et al: Constitutive expression of parathyroid hormone-related protein gene in human T cell leukemia virus type I (HTLV-I) carriers and adult T cell leukemia patients that can be trans-activated by HTLV-I tax gene. J Exp Med 172:759–765, 1990PubMedCrossRefGoogle Scholar
  59. 59.
    Dittmer J, Gitlin S, Reid R, et al: Transactivation of the P2 promoter of parathyroid hormone-related protein by human T-cell lymphotropic virus type I tax,: Evidence for the involvement of transcription factor etsl. J Virol 67:6087–6095, 1993.PubMedGoogle Scholar
  60. 60.
    Taguchi H, Kinoshita KI, Takatsuki K, et al: An intensive chemotherapy of adult T-cell leukemia,lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr Hum Retrovirol 12:182–186, 1996PubMedCrossRefGoogle Scholar
  61. 61.
    Sparano JA, Wiernik PH, Strack M, et al: Infusional cyclophoshamide, doxorubicin, and etoposide in human immunodeficiency virus-, and human T-cell leukemia virus type I-related non-Hodgkin’s lymphoma: A highly active regimen. Blood 81:2810–2815, 1993PubMedGoogle Scholar
  62. 62.
    Tsuda H, Takatsuki K, Ohno R, et al: Treatment of adult T-cell leukemia-lymphoma with irinotecan hydrochloride (CPT-11). Br J Cancer 70:771–774, 1994PubMedCrossRefGoogle Scholar
  63. 63.
    Brito-Babapulle F, Arya R, Griffiths T, et al: BEAM regimen and G-CSF in HTLV-I-associated T-cell lymphoma. Lancet 339:133–134, 1992PubMedCrossRefGoogle Scholar
  64. 64.
    Lofters W, Campbell M, Gibbs N, et al: 2’-Deoxycoformycin therapy in adult T-cell leukemia,lymphoma. Cancer 60:2605–2608, 1987PubMedCrossRefGoogle Scholar
  65. 65.
    Yamaguchi K, Yul LS, Oda T, et al: Clinical consequences of 2’-deoxycoformycin treatment in patients with refractory adult T-cell leukemia. Leuk Res 10:989–993, 1996CrossRefGoogle Scholar
  66. 66.
    Olmo R, Masaoka T, Shirakawa S, et al: Treatment of adult T-cell leukemia,lymphoma with MST-16, a new oral antitumor drug and a derivative of Bis (2,6-dioxopiperazine). Cancer 71:2217–2221, 1993CrossRefGoogle Scholar
  67. 67.
    Tsukasaki K, Ikeda S, Murata K, et al: Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia,lymphoma. Leuk Res 17:157–166, 1993PubMedCrossRefGoogle Scholar
  68. 68.
    Borg A, Yin JA, Johnson PR, et al: Successful treatment of HTLV-I-associated acute adult T-cell leukaemia lymphoma by allogeneic bone marrow transplantation. Br J Hematol 94:713–715, 1996CrossRefGoogle Scholar
  69. 69.
    Ljungman P, Lawler M, Asjo B, et al: Infection of donor lymphocytes with human T lymphotropic virus type 1 (HTLV-I) following allogeneic bone marrow transplantation for HTLV-I positive adult T-cell leukaemia. Br J Hematol 88:403–405, 1994CrossRefGoogle Scholar
  70. 70.
    Miyoshi I, Murata N, Machida H, et al: Transmission of human T-lymphotropic virus type 1 by bone marrow transplantation. Br J Hematol 89:690–691, 1995CrossRefGoogle Scholar
  71. 71.
    Kuwazuru Y, Hanada S, Furukawa T, et al: Expression of P-glycoprotein in adult T-cell leukemia cells. Blood 76:2065–2071, 1990PubMedGoogle Scholar
  72. 72.
    Gill PS, Harrington W, Kaplan MH, et al: Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 332:1744–1748, 1995PubMedCrossRefGoogle Scholar
  73. 73.
    Bazarbachi A, Hermine O: Treatment with a combination of zidovudine and a-interferon in naïve and pretreated adult T-cell leukemia,lymphoma patients. J Acquir Immune Defic Syndr Hum Retrovirol 13 (S 1): S 186–S190, 1996PubMedCrossRefGoogle Scholar
  74. 74.
    Hermine O, Bouscary D, Gessain A, et al: Brief report: Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 332:1749–1751, 1995PubMedCrossRefGoogle Scholar
  75. 75.
    Chan EF, Dowdy YG, Lee B, et al: A novel chemotherapeutic (interferon alfa, zidovudine, and etretinate) for adult T-cell lymphoma resulting in rapid tumor destruction. J Amer Acad Dermatol 40:116–121, 1999CrossRefGoogle Scholar
  76. 76.
    Dierov J, Sawaya B, Prosniak M, et al: Retinoic acid modulates a bimodal effect n cell cycle progression in human adult T-cell leukemia cells. Clin Cancer Res 5:2540–2547, 1999PubMedGoogle Scholar
  77. 77.
    Liu M, Iavarone A, Freedman L: Transcriptional activation of the human p21WAFICIPIgene by retinoic acid receptor. J Biol Chem 271:31723–31728, 1996PubMedCrossRefGoogle Scholar
  78. 78.
    Langenfeld J, Kiyokawa H, Sekula D, et al: Posttranslational regulation of cyclin D1 by retinoic acid: A chemoprevention mechanism. Proc Natl Acad Sci 94:12070–12074, 1997PubMedCrossRefGoogle Scholar
  79. 79.
    Tamura K, Makino S, Araki Y, et al: Recombinant interferon beta and gamma in the treatment of adult T-cell leukemia. Cancer 59:1059–1062, 1987PubMedCrossRefGoogle Scholar
  80. 80.
    Ezaki K, Hirano M, Ohno R, et al: A combination trial of human lymphoblastoid interferon and bestrabucil (KM2210) for adult T-cell leukemia,lymphoma. Cancer 68:695–698, 1991PubMedCrossRefGoogle Scholar
  81. 81.
    Waldmann TA, White JD, Goldman CK, et al: The Interleukin-2 Receptor: A target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 82:1701–1712, 1993PubMedGoogle Scholar
  82. 82.
    Waldmann TA, White JD, Carrasquillo JA, et al: Radioimmunotherapy of interleukin-2Ra-expressing adult T-cell leukemia with Yttriium-90-labeled anti-Tac. Blood 86:4063–4075, 1995PubMedGoogle Scholar
  83. 83.
    Ishitsuka K, Hanada S, Suzuki S, et al: Arsenic trioxide inhibits growth of human T-cell leukemia virus type I infected T-cell lines more effectively than retinoic acids. Br J Hematol 103:721–728, 1998CrossRefGoogle Scholar
  84. 84.
    The GD, Kazanji M: An HTLV-I,II vaccine: From animal models to clinical trials? J Acquir Immune Defic Hum Retrovirol 13(S1):S191–S198, 1996CrossRefGoogle Scholar
  85. 85.
    The GD, Bomford R: An HTLV-I vaccine: Why, how, for whom? AIDS Res Hum Retrovirol 9:381–386, 1993CrossRefGoogle Scholar
  86. 86.
    Berneman ZN, Gartenhaus RB, Reitz MS, et al: Expression of alternatively spliced human T-lymphotropic virus type I pX mRNA in infected cell lines and in primary uncultured cells from patients with adult T-cell leukemia,lymphoma and healthy carriers. Proc Nail Acad Sci 89: 3005–3009, 1992CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Richard Siegel
    • 1
  • Ronald Gartenhaus
    • 1
  • Timothy Kuzel
    • 1
  1. 1.Robert H. Lurie Comprehensive Cancer Center of Northwestern UniversityAmerica

Personalised recommendations